Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Satiatrim is a dietary supplement and nutraceutical primarily utilized for weight management and the regulation of postprandial glucose levels. The active ingredient in Satiatrim is phaseolamin, a proteinaceous alpha-amylase inhibitor extracted from the white kidney bean (*Phaseolus vulgaris*). Phaseolamin functions by competitively binding to the active site of alpha-amylase enzymes in the saliva and pancreas, thereby obstructing the breakdown of dietary starches into oligosaccharides and simple sugars. This inhibition reduces the glycemic index of starchy meals and decreases the total caloric absorption from carbohydrates. Satiatrim is commonly marketed to individuals seeking non-pharmaceutical interventions for obesity, weight loss, and metabolic health support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Satiatrim.